How big is Gossamer Bio, Inc.?

As of Jun 18, Gossamer Bio, Inc. has a market capitalization of 283.00 million and reported net sales of 124.59 million with a net profit loss of 51.24 million over the last four quarters. Shareholder's funds were 29.49 million, and total assets were 315.29 million.

As of Jun 18, Gossamer Bio, Inc. has a market capitalization of 283.00 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 124.59 million for the latest four quarters. During the same period, Gossamer Bio, Inc. experienced a net profit loss of 51.24 million.<BR><BR>As of Dec 24, the company's shareholder's funds stood at 29.49 million, while total assets were reported at 315.29 million.

What does Gossamer Bio, Inc. do?

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunology, inflammation, and oncology. As of March 2025, it has a market cap of $283 million, with net sales of $10 million and a net loss of $37 million.

Overview: <BR>Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 10 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -37 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 283.00 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 9.49 <BR>Return on Equity: 819.81% <BR>Price to Book: -45.28<BR><BR>Contact Details: <BR>Address: 3013 Science Park Rd, SAN DIEGO CA: 92121-1101 <BR>Tel: 1 858 9220718 <BR>Fax: 1 302 6365454 <BR>Website: https://www.gossamerbio.com/

Should I buy, sell or hold Gossamer Bio, Inc.?

Who are in the management team of Gossamer Bio, Inc.?

As of March 2022, Gossamer Bio, Inc.'s management team includes Mr. Faheem Hasnain as Chairman, President, and CEO, along with independent directors Dr. Joshua Bilenker, Ms. Kristina Burow, Mr. Russell Cox, Dr. Thomas Daniel, and Ms. Renee Gala.

As of March 2022, the management team of Gossamer Bio, Inc. includes Mr. Faheem Hasnain, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the Board of Directors features several independent directors: Dr. Joshua Bilenker, Ms. Kristina Burow, Mr. Russell Cox, Dr. Thomas Daniel, and Ms. Renee Gala.

Is Gossamer Bio, Inc. overvalued or undervalued?

As of August 12, 2024, Gossamer Bio, Inc. is considered a risky investment due to its negative valuation ratios and poor long-term performance, despite a strong year-to-date return.

As of 12 August 2024, Gossamer Bio, Inc. has moved from a grade of "does not qualify" to "risky." The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -48.57, an EV to EBIT of -4.46, and an EV to EBITDA of -4.76. In comparison to peers, Rigel Pharmaceuticals, Inc. has a much more favorable P/E ratio of 7.49 and an EV to EBITDA of 6.40, highlighting the significant disparity in valuation.<BR><BR>Despite a strong year-to-date return of 240.48%, which outperformed the S&P 500's 12.22%, the long-term performance is concerning, with a 3-year return of -77.22% compared to the S&P 500's 70.41%. This indicates that while there may be short-term volatility, the overall valuation metrics suggest that Gossamer Bio, Inc. is not a sound investment at its current price.

Is Gossamer Bio, Inc. technically bullish or bearish?

As of October 10, 2025, Gossamer Bio, Inc. shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, but mixed signals from Dow Theory and OBV suggest caution.

As of 10 October 2025, the technical trend for Gossamer Bio, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating a positive momentum. The Bollinger Bands are also showing a mildly bullish stance on both weekly and monthly time frames. However, the Dow Theory presents a mixed view with a mildly bearish signal on the weekly and a mildly bullish signal on the monthly. The moving averages on the daily chart are mildly bullish, but the weekly OBV is mildly bearish, suggesting some selling pressure. Overall, the indicators suggest a mildly bullish stance, but with caution due to mixed signals in the Dow Theory and OBV. Multi-period return data is not available for comparison with the S&P 500.